Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Achillion Pharmaceuticals Inc (ACHN) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Achillion Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1070336.
Total stock buying since 2014: $39,600.
Total stock sales since 2014: $13,535,237,903.
Total stock option exercises since 2014: $13,948,216.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2019 | 0 | $0 | 143,969 | $917,162 | 193,484 | $622,613 |
| 2018 | 0 | $0 | 0 | $0 | 60,000 | $63,000 |
| 2017 | 0 | $0 | 18,367,346 | $50,510,201 | 2,811,245 | $8,751,405 |
| 2016 | 10,000 | $39,600 | 0 | $0 | 0 | $0 |
| 2015 | 0 | $0 | 763,778 | $8,209,918 | 166,625 | $430,375 |
| 2014 | 0 | $0 | 19,858,580 | $13,475,600,622 | 1,244,373 | $4,080,823 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2019-12 | 0 | $0 | 0 | $0 | 20,000 | $65,600 |
| 2019-11 | 0 | $0 | 10,485 | $66,202 | 40,000 | $131,200 |
| 2019-10 | 0 | $0 | 133,484 | $850,960 | 133,484 | $425,813 |
| 2018-12 | 0 | $0 | 0 | $0 | 40,000 | $42,000 |
| 2018-06 | 0 | $0 | 0 | $0 | 20,000 | $21,000 |
| 2017-11 | 0 | $0 | 18,367,346 | $50,510,201 | 0 | $0 |
| 2017-08 | 0 | $0 | 0 | $0 | 2,811,245 | $8,751,405 |
| 2016-12 | 10,000 | $39,600 | 0 | $0 | 0 | $0 |
| 2015-12 | 0 | $0 | 53,500 | $543,480 | 53,500 | $75,875 |
| 2015-11 | 0 | $0 | 550,000 | $5,595,710 | 0 | $0 |
| 2015-09 | 0 | $0 | 9,310 | $76,528 | 0 | $0 |
| 2015-08 | 0 | $0 | 37,843 | $284,200 | 0 | $0 |
| 2015-01 | 0 | $0 | 113,125 | $1,710,000 | 113,125 | $354,500 |
| 2014-09 | 0 | $0 | 8,267,169 | $13,364,194,170 | 0 | $0 |
| 2014-08 | 0 | $0 | 8,261,274 | $85,156,815 | 742,436 | $2,730,084 |
| 2014-06 | 0 | $0 | 3,330,137 | $26,249,637 | 501,937 | $1,350,739 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-12-18 | Van Nostrand Robert L | Option Ex | 20,000 | 3.28 | 65,600 |
| 2019-11-14 | Fisherman Jason S | Option Ex | 20,000 | 3.28 | 65,600 |
| 2019-11-13 | Scheer David | Sale | 10,485 | 6.31 | 66,202 |
| 2019-11-13 | Scheer David | Option Ex | 20,000 | 3.28 | 65,600 |
| 2019-10-16 | Truitt Joseph (Chief Executive Officer) | Sale | 133,484 | 6.38 | 850,960 |
| 2019-10-16 | Truitt Joseph (Chief Executive Officer) | Option Ex | 133,484 | 3.19 | 425,813 |
| 2018-12-14 | Scheer David (Director) | Option Ex | 20,000 | 1.05 | 21,000 |
| 2018-12-14 | Van Nostrand Robert L (Director) | Option Ex | 20,000 | 1.05 | 21,000 |
| 2018-06-06 | Fisherman Jason S (Director) | Option Ex | 20,000 | 1.05 | 21,000 |
| 2017-11-20 | Johnson & Johnson Innovation - Jjdc, Inc. (10% Owner) | Sale | 18,367,346 | 2.75 | 50,510,201 |
| 2017-08-10 | Vitullo Nicole (Director) | Option Ex | 2,811,245 | 3.11 | 8,751,405 |
| 2016-12-22 | Fisherman Jason S (Director) | Buy | 10,000 | 3.96 | 39,600 |
| 2015-12-30 | Apelian David (Chief Medical Officer) | Sale | 10,000 | 10.50 | 105,000 |
| 2015-12-30 | Apelian David (Chief Medical Officer) | Option Ex | 10,000 | 3.02 | 30,200 |
| 2015-12-28 | Fenton Mary Kay (Chief Financial Officer) | Sale | 43,500 | 10.08 | 438,480 |
| 2015-12-28 | Fenton Mary Kay (Chief Financial Officer) | Option Ex | 43,500 | 1.05 | 45,675 |
| 2015-11-11 | Vitullo Nicole (Director) | Sale | 50,000 | 10.31 | 515,500 |
| 2015-11-10 | Vitullo Nicole (Director) | Sale | 179,074 | 10.43 | 1,867,741 |
| 2015-11-09 | Vitullo Nicole (Director) | Sale | 320,926 | 10.01 | 3,212,469 |
| 2015-09-25 | Vitullo Nicole (Director) | Sale | 9,310 | 8.22 | 76,528 |
| 2015-08-14 | Vitullo Nicole (Director) | Sale | 37,843 | 7.51 | 284,200 |
| 2015-01-23 | Fenton Mary Kay (EVP and CFO) | Sale | 13,125 | 16.00 | 210,000 |
| 2015-01-23 | Fenton Mary Kay (EVP and CFO) | Option Ex | 13,125 | 4.00 | 52,500 |
| 2015-01-21 | Deshpande Milind (President and CEO) | Sale | 100,000 | 15.00 | 1,500,000 |
| 2015-01-21 | Deshpande Milind (President and CEO) | Option Ex | 100,000 | 3.02 | 302,000 |
| 2014-09-30 | Ra Capital Healthcare Fund Lp | Sale | 1,111,000 | 10.06 | 11,176,660 |
| 2014-09-29 | Ra Capital Healthcare Fund Lp | Sale | 221,014 | 10.96 | 2,423,197 |
| 2014-09-26 | Ra Capital Healthcare Fund Lp | Sale | 670,000 | 11.06 | 7,408,190 |
| 2014-09-25 | Ra Capital Healthcare Fund Lp | Sale | 497,986 | 11.04 | 5,499,259 |
| 2014-09-24 | Ra Capital Healthcare Fund Lp | Sale | 1,204,929 | 11.26 | 13,571,115 |
| 2014-09-23 | Ra Capital Healthcare Fund Lp | Sale | 984,522 | 11.08 | 10,905,550 |
| 2014-09-22 | Ra Capital Healthcare Fund Lp | Sale | 445,689 | 11.09 | 4,941,799 |
| 2014-09-19 | Ra Capital Healthcare Fund Lp | Sale | 1,164,860 | 11.67 | 13,589,256 |
| 2014-09-11 | Kolchinsky Peter | Sale | 1,181,912 | 12.39 | 14,646,253 |
| 2014-09-10 | Kolchinsky Peter | Sale | 522,450 | 25,412.73 | 13,276,881,310 |
| 2014-09-02 | Kolchinsky Peter | Sale | 262,807 | 11.99 | 3,151,581 |
| 2014-08-29 | Kolchinsky Peter | Sale | 398,845 | 11.44 | 4,561,191 |
| 2014-08-28 | Kolchinsky Peter | Sale | 173,641 | 11.51 | 1,999,302 |
| 2014-08-27 | Kolchinsky Peter | Sale | 267,089 | 11.61 | 3,101,170 |
| 2014-08-26 | Kolchinsky Peter | Sale | 2,112,867 | 11.53 | 24,352,905 |
| 2014-08-25 | Truitt Joseph (EVP, Chief Commercial Officer) | Sale | 25,000 | 10.82 | 270,500 |
| 2014-08-25 | Truitt Joseph (EVP, Chief Commercial Officer) | Option Ex | 25,000 | .82 | 20,500 |
| 2014-08-25 | Kolchinsky Peter | Sale | 331,396 | 10.97 | 3,636,739 |
| 2014-08-18 | Deshpande Milind (President and CEO) | Sale | 216,624 | 10.00 | 2,166,240 |
| 2014-08-18 | Deshpande Milind (President and CEO) | Option Ex | 216,624 | 2.86 | 619,111 |
| 2014-08-18 | Ra Capital Healthcare Fund Lp | Sale | 1,993,978 | 9.66 | 19,255,845 |
| 2014-08-15 | Ra Capital Healthcare Fund Lp | Sale | 2,241,022 | 9.41 | 21,083,534 |
| 2014-08-15 | Kishbauch Michael D (Director) | Sale | 495,812 | 9.46 | 4,689,389 |
| 2014-08-15 | Kishbauch Michael D (Director) | Option Ex | 495,812 | 4.18 | 2,074,973 |
| 2014-08-13 | Frashier Gary E (Director) | Sale | 5,000 | 8.00 | 40,000 |
| 2014-08-13 | Frashier Gary E (Director) | Option Ex | 5,000 | 3.10 | 15,500 |
| 2014-06-20 | Ra Capital Management, Llc | Sale | 880,000 | 8.35 | 7,349,760 |
| 2014-06-16 | Truitt Joseph (EVP, Chief Commercial Officer) | Sale | 25,000 | 7.82 | 195,500 |
| 2014-06-16 | Truitt Joseph (EVP, Chief Commercial Officer) | Option Ex | 25,000 | .82 | 20,500 |
| 2014-06-16 | Qvt Associates Gp Llc (10% Owner) | Sale | 1,819,551 | 7.75 | 14,094,242 |
| 2014-06-16 | Frashier Gary E (Director) | Sale | 55,000 | 8.00 | 440,000 |
| 2014-06-16 | Frashier Gary E (Director) | Option Ex | 55,000 | 2.48 | 136,235 |
| 2014-06-11 | Qvt Associates Gp Llc (10% Owner) | Sale | 87,024 | 7.64 | 664,863 |
| 2014-06-10 | Truitt Joseph (EVP, Chief Commercial Officer) | Sale | 48,950 | 6.05 | 296,147 |
| 2014-06-10 | Truitt Joseph (EVP, Chief Commercial Officer) | Option Ex | 48,950 | .82 | 40,139 |
| 2014-06-10 | Qvt Associates Gp Llc (10% Owner) | Sale | 41,625 | 7.72 | 321,553 |
| 2014-06-10 | Kishbauch Michael D (Director) | Sale | 371,937 | 7.75 | 2,882,511 |
| 2014-06-10 | Kishbauch Michael D (Director) | Option Ex | 371,937 | 3.10 | 1,153,004 |
| 2014-06-09 | Truitt Joseph (EVP, Chief Commercial Officer) | Sale | 1,050 | 4.82 | 5,061 |
| 2014-06-09 | Truitt Joseph (EVP, Chief Commercial Officer) | Option Ex | 1,050 | .82 | 861 |
Insider trading activities including stock purchases, stock sales, and option exercises of ACHN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Achillion Pharmaceuticals Inc (symbol ACHN, CIK number 1070336) see the Securities and Exchange Commission (SEC) website.